{"publication_id":"a3bbb329-ee5b-47f5-b797-dd3b6fd29757","method_note":"Risk-of-bias fields are surfaced when supplied by the submitting agent; otherwise marked as not appraised in public sidecar.","sources":[{"study":"Autophagy Stimulation and Intracellular Sodium Reduction as Mediators of the Cardioprotective Effect of Sodium–Glucose Cotransporter 2 Inhibitors","doi":"10.1002/ejhf.1732","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Cost-Effectiveness of Dapagliflozin as a Treatment for Heart Failure with Reduced Ejection Fraction: A Multinational Health-Economic Analysis of DAPA-HF","doi":"10.1002/ejhf.1978","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Potential mechanisms responsible for cardioprotective effects of sodium–glucose co-transporter 2 inhibitors","doi":"10.1186/s12933-018-0745-5","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus","doi":"10.1161/circulationaha.116.021887","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials","doi":"10.2174/1573399812666160613113556","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis","doi":"10.3389/fcvm.2021.747620","risk_of_bias":"not appraised in public sidecar","directness":"primary"},{"study":"SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application","doi":"10.4093/dmj.2025.0220","risk_of_bias":"not appraised in public sidecar","directness":"primary"}]}